What is thalassemia, what are its types, how is it diagnosed, and what treatments are available?

What is Thalassemia and Its Types, Diagnosis, and Treatment

Definition

Thalassemia is a genetic blood disorder characterized by severe reduction or absent production of specific globin chains of hemoglobin, resulting in ineffective erythropoiesis, chronic hemolytic anemia, and variable clinical severity ranging from asymptomatic carriers to life-threatening disease requiring lifelong transfusions. 1, 2

The condition is most prevalent in populations with historical malaria exposure, including Asia, the Middle East, and Mediterranean Europe 1.

---

Types of Thalassemia

β-Thalassemia (Beta-Thalassemia)

1. β-Thalassemia Major (Transfusion-Dependent)

• Severe reduction or absent β-globin chain production causing profound anemia that becomes life-threatening from 1-2 years of age 1
• Requires >8 transfusion events per year in adults >16 years 1
• Untreated patients develop: growth retardation, pallor, jaundice, hepatosplenomegaly, skeletal deformities from bone marrow expansion, and masses from extramedullary hematopoiesis 2
• Transfused patients develop: iron overload complications including endocrine dysfunction (growth failure, delayed puberty, diabetes, thyroid/parathyroid/pituitary insufficiency), dilated cardiomyopathy, liver fibrosis and cirrhosis 2

2. β-Thalassemia Intermedia (Non-Transfusion-Dependent)

• Moderate anemia presenting later in life, generally not requiring regular transfusions 1
• Key complications: erythroid marrow hypertrophy with extramedullary hematopoiesis, osteoporosis, gallstones, painful leg ulcers, increased thrombosis risk, pulmonary hypertension 1, 2
• Variable gastrointestinal iron uptake; may require transfusions as patients age to prevent cardiovascular complications 1

3. β-Thalassemia Minor (Trait)

• Clinically asymptomatic carriers with mild or moderate anemia 2
• Normal life expectancy 3

α-Thalassemia (Alpha-Thalassemia)

The evidence focuses primarily on β-thalassemia, but α-thalassemia follows similar patterns with reduced or absent α-globin chain synthesis 3. Forms include silent carriers, α-thalassemia trait, hemoglobin H disease (α-thalassemia intermedia), and hemoglobin Bart's (α-thalassemia major, usually fatal) 3.

---

Diagnosis

Hematologic Testing

• Complete blood count: Microcytic hypochromic anemia with reduced hemoglobin
• Hemoglobin electrophoresis: Identifies abnormal hemoglobin patterns
• Bone marrow examination: Shows ring sideroblasts in some cases 4
• Iron studies: Elevated serum ferritin and transferrin saturation, even before transfusions begin 4

Molecular Genetic Testing

• Point mutations or deletions in β-globin gene on chromosome 11 2
• Autosomal recessive inheritance (dominant mutations rarely reported) 2
• Prenatal diagnosis available using fetal DNA samples for single point mutation detection 5

Cardiac Assessment (Critical for β-Thalassemia Major)

• T2 cardiac MRI:* Gold standard for measuring cardiac iron loading since 2001 1
  • T2* <20 ms indicates cardiac iron overload
  • T2* <6 ms carries 47% risk of heart failure within 1 year 1
• Echocardiography: Assess left ventricular ejection fraction (LVEF) and cardiac function 1
• BNP levels: Elevated in heart failure 1

---

Treatment

β-Thalassemia Major: Core Management

1. Regular Blood Transfusions

Maintain pre-transfusion hemoglobin 9-10 g/dL and post-transfusion hemoglobin 13-14 g/dL to suppress ineffective erythropoiesis while balancing iron loading and symptom relief 1. This reduces blood volume expansion and cardiac index 1.

2. Iron Chelation Therapy (Lifelong)

Each transfusion unit contains ~200 mg iron, combined with increased gastrointestinal absorption, necessitating lifelong chelation 1.

Available chelators:

• Deferiprone: Superior efficacy versus deferoxamine for cardiac iron removal 1
• Deferoxamine: Standard therapy; combined with deferiprone shows superiority over deferoxamine alone 1
• Deferasirox: Equivalent to deferoxamine 1

Critical caveat: Deferiprone may increase neutropenia risk; switch to deferoxamine during antiviral hepatitis C treatment 6. Deferasirox should be avoided in acute heart failure with marginal renal perfusion 1.

3. Cardiac Iron Management by T2 Level*

• T2 <6 ms:* Treat as acute heart failure with maximal chelation 1
• T2 6-10 ms:* Intensified but not necessarily maximal chelation 1
• T2 10-20 ms:* Conservative management with dose modifications, compliance improvement, or alternative chelators 1

Acute Decompensated Heart Failure Protocol

This is a medical emergency requiring immediate specialist center involvement 1. Historical mortality was 50% within 1 year; modern intensive chelation improves survival to 85-100% 1.

Immediate management:

1. Start continuous 24-hour intravenous deferoxamine 50 mg/kg/day immediately 1
2. Continuous ECG and hemodynamic monitoring 1
3. Bedside echocardiography to confirm diagnosis 1
4. Add deferiprone 75 mg/kg/day (divided in 3 doses) as soon as possible 1
5. Maintain cerebral and renal perfusion; avoid aggressive inotropes 1
6. Use minimum diuretics to maintain preload (critical difference from standard heart failure management) 1

Important: Clinical stabilization occurs within 14 days to months; cardiac iron removal requires years of continued chelation 1.

β-Thalassemia Intermedia Management

• Splenectomy when indicated
• Folic acid supplementation
• Treatment of extramedullary masses and leg ulcers
• Prevention and therapy of thromboembolic events
• Iron chelation if transfusions become necessary 1, 2

Curative Options

Hematopoietic Stem Cell Transplantation (HSCT)

HSCT remains the only definitive cure currently available 7, 2.

Optimal timing and selection:

• Perform as soon as possible in young children with HLA-matched sibling donors to avoid transfusion-related complications 7
• Modern approaches achieve 91% overall survival and disease-free survival in low-risk children with matched sibling donors 7
• Transplant-related mortality has fallen to ≤5% in young, low-risk children 7
• Patient status at transplantation is the critical predictor of outcome—perform before iron-related organ damage develops 7

Risk stratification (Pesaro classification):

• Age, hepatomegaly, and portal fibrosis are key risk factors 7
• Best outcomes in Class I patients (young, minimal organ damage) 7

Gene Therapy

First successful case reported with Phase I clinical trials underway 7. Currently limited to industrialized countries 7.

Monitoring and Complications Management

• Endocrine surveillance: Screen before age 10 in transfusion-dependent patients 8
• Hepatitis C treatment: Peginterferon plus ribavirin; requires multidisciplinary approach with increased transfusion support (30-40% increase) 6
• Splenectomy: May be required in some circumstances 2, 5
• Cardiac monitoring: Regular T2* MRI and LVEF assessment to guide chelation intensity 1

---

Prognosis

With modern transfusion and iron chelation therapy, survival into the fourth or fifth decade is now possible for well-treated β-thalassemia major patients 7. However, cardiac disease from iron overload remains the predominant cause of death 1, 2, 3. Early detection and aggressive treatment of cardiac iron loading before heart failure develops is critical for survival 1.

Thalassemia trait carriers have normal life expectancy 3.